NEC member Sunovion Pharmaceuticals, headquartered in Marlborough, MA, has received FDA approval for a Parkinson’s Disease (PD) medication that helps treat disruptive episodes of worsened PD symptoms.
The drug, KYNMOBI, dissolves under the tongue and can be administered as episodes occur. It is the first sublingual, fast-acting therapy for motor control symptoms associated with Parkinson’s Disease, and can be taken up to five times a day. Patients have seen significant improvement in motor function within 30 minutes of taking KYNMOBI. Approximately 60% of Parkinson’s patients experience OFF episodes within four to six years of their diagnosis.
“Today’s approval of KYNMOBI advances treatment options for people with Parkinson’s disease who experience OFF episodes and the associated disruption of everyday activities,” said Antony Loebel, M.D., President and CEO at Sunovion. “We are pleased to offer the Parkinson’s disease community a novel treatment option that we believe offers a convenient way for patients to rapidly improve impaired movements and better control their motor symptoms when they need it.”